Loading...
Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma.
Lee, Rebecca J Gremel, Gabriela Marshall, A Myers, K Fisher, N Dunn, J Dhomen, Nathalie Corrie, P Middleton, M Lorigan, Paul C
Lee, Rebecca J
Gremel, Gabriela
Marshall, A
Myers, K
Fisher, N
Dunn, J
Dhomen, Nathalie
Corrie, P
Middleton, M
Lorigan, Paul C
Citations
Altmetric:
Abstract
Patients with high-risk stage II/III resected melanoma commonly develop distant metastases. At present, we cannot differentiate between patients who will recur or those who are cured by surgery. We investigated if circulating tumor DNA (ctDNA) can predict relapse and survival in patients with resected melanoma.
Description
Date
2017-11-03
Publisher
Collections
Files
Keywords
Type
Article
Citation
Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma. 2017 Ann Oncol